No safety concerns were detected in any of the studies.<ref name=":0" /><ref name=":4" /><ref name=":5" /><ref name=":6" /> A few patients suffered from mild infusion reactions that resolved on their own.<ref name=":0" /><ref name=":4" /> The measured laboratory values and vital signs, showed no changes.<ref name=":4" /> Other adverse events that occurred, e.g., [[headache]] or [[hematoma]], where not considered as related to treatment.<ref name=":0" /><ref name=":4" />

 


 
Other anti-amyloid beta antibodies caused [[amyloid-related imaging abnormalities]],<ref name=":0" /> which is not the case for solanezumab.<ref name=":0" /><ref name=":4" /><ref name=":5" />

 

